Comparison of different sustained-release opioids and acute respiratory conditions in patients with cancer and chronic kidney disease.

Autor: Mitsuboshi S; Department of Pharmacy, Kaetsu Hospital, Niigata, Japan.; Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan., Imai S; Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan., Kizaki H; Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan., Hori S; Division of Drug Informatics, Keio University Faculty of Pharmacy, Tokyo, Japan.
Jazyk: angličtina
Zdroj: Pharmacotherapy [Pharmacotherapy] 2024 Feb; Vol. 44 (2), pp. 122-130. Date of Electronic Publication: 2023 Nov 21.
DOI: 10.1002/phar.2892
Abstrakt: Study Objective: Few data are available on the association between the use of oxycodone in patients with chronic kidney disease (CKD) and acute respiratory conditions. The aim of this study was to investigate whether oxycodone is associated with an increased risk of acute respiratory conditions in patients with cancer and CKD compared with other opioids.
Design and Setting: The data were obtained from a claims database in Japan. Patients with cancer and CKD who had received sustained-release opioids, including oral oxycodone, oral morphine, or transdermal fentanyl, between April 2014 and May 2021 were selected. The primary outcome was defined as an acute respiratory condition. Data for age and sex, morphine equivalent daily dose, concomitant use of specified medications, comorbidities defined based on the modified Charlson comorbidity index, substance use disorder, and lung cancer or metastatic lung cancer were investigated as covariates. Distribution of acute respiratory conditions was compared among the three sustained-release opioid groups using the log-rank test. Estimates of the incidence of acute respiratory conditions were compared among the groups using a Cox proportional hazards model with time-varying variables.
Main Results: A significant difference in the distribution of acute respiratory conditions was found among the three groups (p < 0.01). Cox regression analysis showed a significantly higher risk of acute respiratory conditions with morphine (hazard ratio [HR]: 3.04, 95% confidence interval [CI]: 1.07-8.65, p = 0.04) compared with oxycodone but no significant difference in risk with oxycodone (HR 0.67, 95% CI: 0.32-1.38, p = 0.27) compared with fentanyl.
Conclusions: The findings suggest that the risk of acute respiratory conditions may be lower in patients with CKD who use oxycodone for cancer pain than in those who use morphine. Additionally, no difference in the risk of acute respiratory conditions was found between oxycodone and fentanyl use.
(© 2023 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.)
Databáze: MEDLINE
Externí odkaz: